Precision BioSearch is delighted to congratulate Tom Coulter on his appointment as Head, Drug Discovery Programs and Partnerships with Dalriada Drug Discovery. Precision BioSearch partnered with Canada’s leading small molecule drug discovery company to secure their first international executive appointment.

Dr. Tom Coulter is a significant addition to their R&D leadership team and will oversee all partnership activities, drug discovery program planning and execution, as well as lifecycle management for current and prospective Dalriada partners.

Dr. Diana Kraskouskaya, CEO and Co-founder, commented: “Precision BioSearch have provided fantastic support in securing Dalriada’s first leadership hire in Europe. Their thorough market research yielded a very strong shortlist of high calibre candidates in an impressively short timeframe. The depth of their expertise was clear to see and they are a pleasure to work with.”

About Dalriada Drug Discovery: Founded in 2017, Dalriada is a small molecule drug discovery company supporting global innovators through its unique Turn-Key™ operation model, offering the biotechnology industry a full suite of drug discovery, preclinical development, intellectual property, and business expertise to manage and execute tailored R&D programs. Founded in 2017 by two prominent PhD chemists, the company builds focused expert teams in MedChem, Biology and ADME to allow for rapid project advancements and value building.

For more information, visit: www.dalriadatx.com